Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal

Ali Al‐Janabi; Zarif K. Jabbar‐Lopez; Christopher Em Griffiths; Zenas Z N Yiu

doi:10.1111/bjd.17624

Abstract

1 min read

Gordon et al. conclude that risankizumab has a higher efficacy than placebo and ustekinumab in the treatment of moderate-to-severe chronic plaque psoriasis, and that the adverse-event profiles were similar across all treatment groups.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2019

Risankizumab vs. ustekinumab for plaque psoriasis

Ali Al‐Janabi, Zarif K. Jabbar‐Lopez, Christopher Em Griffiths, Zenas Z N Yiu

Article2012

Does p40‐targeted therapy represent a significant evolution in the management of plaque psoriasis?

Christopher Em Griffiths, Giampiero Girolomoni

Article2020

Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review

Ali Al‐Janabi, Amy Foulkes, K.J. Mason, Catherine Smith, Christopher Em Griffiths, Richard B. Warren

Editorial Material2012

Biologics for psoriasis: current evidence and future use

Christopher Em Griffiths

Article2025

Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis

Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, Tiago Torres, Zoran Popmihajlov, Ying-Ming Jou, Misti Linaberry, Carolin Daamen, Christopher Em Griffiths